Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.
Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, Lin SY, Scott KL, Peng G, Brugge J, Mills GB.
Sun C, et al. Among authors: peng g.
Sci Transl Med. 2017 May 31;9(392):eaal5148. doi: 10.1126/scitranslmed.aal5148.
Sci Transl Med. 2017.
PMID: 28566428
Free PMC article.